Cambridge Cognition Ltd is the leading global provider of cognitive assessment software for clinical trials, research and healthcare provision. They bring to the Alliance expertise in the area of cognition and cognitive assessments, as well as providing a tool for the assessment of clinically significant memory impairments and depression.
The Cambridge Neuropsychological Test Automated Battery (CANTAB) was originally developed at The University of Cambridge in the 1980s by renowned neuroscientists, Professors Barbara Sahakian and Trevor Robbins.
The neuropsychological tests used in CANTAB technology have been continually enhanced by Cambridge Cognition since 2002. The computer-based cognitive assessment systems are designed for specific use in clinical and academic research studies, as well as healthcare settings. The tests are administered to subjects using a touchscreen computer on iPads, which will be provided along with full training and ongoing support to healthcare practitioners.
CANTAB Mobile is a sensitive assessment tool designed for healthcare professionals to identify the earliest signs of clinically significant memory impairment which may be indicative of Alzheimer’s disease. The assessment comprises three tests: the Paired Associates Learning (PAL) test to assess episodic memory; the Geriatric Depression Scale (GDS) to identify signs of depression and an Activities of Daily Living questionnaire (ADL) to assess functionality in daily life. Both the PAL and GDS tests will be completed by all patients and the ADL will only be completed by patients whose memory performance is below the expected range. Using the normative data built-in to the software, the patient’s performance is automatically compared to other people of the same age, gender and level of education. The standardised scoring ensures consistent interpretation of the results. The reports are available to view immediately and are easy to interpret by the healthcare practitioner. Overall the CANTAB Mobile assessment takes 10 minutes and is currently available in 20 different languages.
CANTAB Mobile will be used to monitor those at a high risk of developing dementia, people with; diabetes, mid-life high blood pressure and high blood cholesterol levels; mid-life obesity; heart problems (such as a heart attack or irregular heart rhythms); stroke. By assessing an individual’s memory performance and mood, the appropriate level of care can be given, including suggesting life-style modifications. The aim is to help those at risk stay safely in their homes for longer and also to prevent a costly acute admission into A&E.
CANTAB Mobile has been used in over 40 CCGs in the UK and to date over 22,500 assessments have been completed.
You can read further case studies of CANTAB Mobile in use in Doncaster CCG and within a pharmacy setting here: